References
- Langley P. Validation of modeled pharmacoeconomic claims in formulary submissions. J Med Econ 2015; 18(12): 993-999
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013: Reference Case London: NICE, 2013. https://www.nice.org.uk/article/pmg9/chapter/the-reference-case. Accessed 28 August 2015
- IFNB MS Study Group and UBC MS/MRI Study Group Interferon β-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
- NHS Executive. New drugs for multiple sclerosis. EL (95)97. Leeds: NHSE, 1995
- NICE. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE technology appraisal guidance 32. London: NICE, 2002. www.guidance.nice.org.uk/ta32. Accessed 28 August 2015
- Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. HSC 2002/004. London: Department of Health, 2002
- Pickin M, Cooper CL, Chater T, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study–early results and lessons for the future. BMC Neurol 2009;9:1
- Palace, Duddy M, Bregenzer T, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol 2015;14:497-505
- NICE. Summary of VELCADE® Response Scheme. London: NICE, 2007. http://www.nice.org.uk/guidance/ta129/documents/department-of-health-summary-of-responder-scheme2. Accessed 28 August 2015
- NICE. Cetuximab for the first line treatment of metastatic colorectal cancer (mCRC). London: NICE, 2008. http://www.nice.org.uk/guidance/ta176/documents/merckserono-updated-patient-access-scheme-documentation2. Accessed 28 August 2015
- Williamson S. A report into the uptake of patient access schemes in the NHS. North Shields: Cancer Network Pharmacist Forum, 2009. http://www.bopawebsite.org/contentimages/publications/Report_into_Uptake_of_Patient_Access_Schemes_8_11_09.pdf. Accessed 28 August 2015
- NICE. Pazopanib for the first-line treatment of advanced renal cell carcinoma. NICE technology appraisal guidance 215. London: NICE, 2011. www.guidance.nice.org.uk/ta215. Accessed August 2013
- Fisher RA. The arrangement of field experiments. J Ministry Agricult Great Britain 1926;33:503-13
- Schommer J, Carlson A, Rhee G. Validating pharmaceutical product claims: questions a formulary committee should ask. J Med Econ 2015; 18(12): 1000-1006